A strategic framework for novel drug development in multiple myeloma.
Anderson
Kenneth C
KC
Department of Medicine, Harvard Medical School, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA. kenneth_anderson@dfci.harvard.edu
Hannah
Alison L
AL
Pazdur
Richard
R
Farrell
Ann T
AT
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D017321:Clinical Trials, Phase I as Topic / Q000379:methods; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D004359:Drug Therapy, Combination; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor